Abstract
The survival rates of many cancers have significantly improved due to recent advancements in cancer screening and therapeutics. Although better cancer outcomes are encouraging, additional health challenges have surfaced, the utmost of which is the burden imposed by various cardiovascular and renal toxicities of anticancer therapies. To improve the overall outcome of patients with cancer, it is essential to understand and manage these treatment-related adverse effects. The cardiovascular side effects of antineoplastic therapies are well-known and include left ventricular dysfunction, heart failure, myocardial ischaemia, QT prolongation, arrhythmia and hypertension. Among these, hypertension is the most common complication, prevalent in about 40% of all cancer patients, yet frequently overlooked and undertreated. This review explores the intricate connection between cancer and hypertension and provides distinct approaches to diagnosing, monitoring and managing hypertension in patients with cancer. We also outline the challenges and considerations that are relevant to the care of patients receiving anticancer drugs with prohypertensive potential.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2336-2348 |
| Number of pages | 13 |
| Journal | Clinical Kidney Journal |
| Volume | 16 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 1 2023 |
Keywords
- VEGF signalling pathway inhibitors
- blood pressure management
- cancer
- cardio-oncology
- onco-hypertension
- onco-nephrology
ASJC Scopus subject areas
- Nephrology
- Transplantation